Pfizer's Arena goal? Get out of the way and don't 'break the new toy'

Pfizer wasn’t about to meddle with the good work being done at Arena Pharmaceuticals, a biotech that attracted the Big Pharma into a $6.7 billion deal in December 2021.

“The worst thing we could do is come in and break the new toy,” Pfizer’s Michael Corbo, chief development officer for inflammation and immunology, told Fierce Biotech in an interview.